Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo JOURNAL OF MEDICINAL CHEMISTRY Lu, J., Chong, C. R., Hu, X., Liu, J. O. 2006; 49 (19): 5645–48

Abstract

The fumagillin family of natural products inhibits angiogenesis through the irreversible inhibition of the type 2 methionine aminopeptidase (MetAP2). Herein is reported a novel fumagillin analogue named fumarranol. It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and endothelial cell proliferation. It is also active in a mouse model of angiogenesis in vivo. Unlike TNP-470, fumarranol does not covalently bind to MetAP2. Fumarranol may serve as a lead for a new class of angiogenesis inhibitors.

View details for DOI 10.1021/jm060559v

View details for Web of Science ID 000240495600001

View details for PubMedID 16970390